Good effect of IgY against Pseudomonas aeruginosa infections in cystic fibrosis patients
This is an extended open study of oral prophylactic treatment with egg yolk antibodies against Pseudomonas aeruginosa, Anti‐Pseudomonas IgY, of 17 Swedish patients with cystic fibrosis. They have been on prophylactic IgY treatment for up to 12 years and altogether for 114 patient years. A group of 2...
Saved in:
Published in: | Pediatric pulmonology Vol. 43; no. 9; pp. 892 - 899 |
---|---|
Main Authors: | , , , , |
Format: | Journal Article |
Language: | English |
Published: |
Hoboken
Wiley Subscription Services, Inc., A Wiley Company
01-09-2008
Wiley-Liss |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | This is an extended open study of oral prophylactic treatment with egg yolk antibodies against Pseudomonas aeruginosa, Anti‐Pseudomonas IgY, of 17 Swedish patients with cystic fibrosis. They have been on prophylactic IgY treatment for up to 12 years and altogether for 114 patient years. A group of 23 Danish CF patients served as control. There has been a total absence of adverse events. Only 29 cultures have been positive for P. aeruginosa (cultures after chronic colonization not included), that is, 2.3/100 treatment months compared to 7.0/100 months in the control group (P = 0.028). In the IgY treated group only one pair of siblings (2/17) has been chronically colonized with P. aeruginosa compared to seven patients (7/23) in the control group. Atypical mycobacteria, S. maltophilia, A. xylosoxidans, and A. fumigatus have appeared only sporadically. There have been no cultures positive for B. cepacia. There was no decrease in pulmonary functions (P = 0.730) within the IgY group. Body mass index values were normal or close to normal for all IgY treated patients. In conclusion, Anti‐Pseudomonas IgY has great potential to prevent P. aeruginosa infections. Pediatr Pulmonol. 2008; 43:892–899. © 2008 Wiley‐Liss, Inc. |
---|---|
Bibliography: | ArticleID:PPUL20875 Presented at the 21st Annual North American CF Conference, Anaheim, California, USA, October 2007 and at the 3rd National Infection Biology Meeting, Uppsala, Sweden, November 2007. Ekhagastiftelsen Uppsala University Hospital Research Fund istex:02AD12901FE47E558F0562624B619938B4A9F2BA ark:/67375/WNG-HDRJXWZ9-W ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 8755-6863 1099-0496 1099-0496 |
DOI: | 10.1002/ppul.20875 |